Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)-MedSci.cn - 梅斯（MedSci）

Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)

Qian, K; Chen, QR; He, M; Wang, ZT; Liu, Y; Liang, HG; Su, ZY; Cui, YS; Liu, LJ; Zhang, Y

Zhang, Y (通讯作者)，Capital Med Univ, Xuanwu Hosp, Dept Thorac Surg, 45 Changchun St, Beijing 100053, Peoples R China.

INVESTIGATIONAL NEW DRUGS, 2023; 41 (1): 44

Abstract

The survival benefit of icotinib (an oral epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor) in patients with advanced lung cancer has......

Full Text Link

Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

科室
- - 订阅+
  - 更多科室
工具
服务